VetStem enters pet cancer space with immunotherapy licence from human health firm

摘要

US company VetStem Biopharma has negotiated an exclusive licence to Calidi Biotherapeutics' immunotherapy for the development of a pet cancer treatment. Calidi is developing biotechnology for stem cell-based delivery of oncolytic virus-based immunotherapies for human cancer. The global licence allows VetStem to develop and commercialize Calidi's lead SuperNova1 drug, which is currently in phase II clinical trials in humans.The agreement will provide Calidi with development milestone payments and downstream royalties from VetStem. Both companies are based in San Diego.